Skanska to build for pharmaceutical company in New Jersey for USD 60.5 M, about SEK 410 M

Skanska has been chosen as construction manager for expansion of a pharmaceutical facility in New Jersey. The contract amount totals USD 60.5 M, or approximately SEK 410 M, which will be included in order bookings for the fourth quarter. The customer is one of Skanska’s repeat customers within the pharmaceutical industry.

The project involves construction of a three-story, approximately 9.300-square-meter building and renovation of an existing 11,600-square-meter building. Among other objectives, the project will improve and expand the company’s supply operations and logistics management.

This is the fifth project that Skanska is performing at the facility since 2005. Previous projects include office and laboratory renovations, a new parking deck, cafeteria and fitness center as well as a new clinical manufacturing structure.

Skanska USA Building is a leading U.S. provider of construction, general contracting, design and design-build services. The company also provides pharmaceutical validation services to clients. Customers represent a broad spectrum of American industries, including the pharmaceutical, healthcare, educational, electronics, infrastructure, sports and entertainment industries. The company is based in Parsippany, New Jersey and has approximately 3,900 employees. Revenues totaled approximately SEK 30 billion in 2006.

In addition to a number of biotechnology facilities throughout the U.S. and Puerto Rico, Skanska USA Building is currently constructing the New Meadowlands Stadium and managing an extensive renovation of UN Headquarters in New York City.




For further information please contact:

Tom Crane, Senior Vice President Communication,
Skanska USA Building, tel +1 973 753 3450
Peter Gimbe, Press Officer, Skanska AB, tel +46 8 753 88 38
Direct line for the media: +46 8 753 88 99